Addition of Isatuximab-irfc to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma IKEMA Trial – The ASCO Post

By Matthew Stenger Posted: 6/21/2021 12:25:00 PM Last Updated: 6/21/2021 11:44:39 AM As reported in The Lancet by Philippe Moreau, MD, and colleagues, the phase III IKEMA trial has shown that the addition of the anti-CD38 antibody isatuximab-irfc to carfilzomib and dexamethasone resulted in significantly…

Read the full article here

Related Articles